Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis;Intérêts des explorations fonctionnelles respiratoires et des études des biomarqueurs dans le diagnostic et le suivi évolutif de la pneumopathie interstitielle diffuse dans la sclérodermie systémique

Revue de Pneumologie Clinique

Volumn 70, Issue 6, 2014, Pages 335-342

  Hua Huy, T ^a   Riviere S ^b   Tiev, K P ^c   Dinh Xuan, A T ^a  

^a Sorbonne Paris Cité ^*  (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c service de médecine interne   (France)

Author keywords

Biomarkers; Interstitial lung disease; Nitric oxide; Pulmonary function tests; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; NITRIC OXIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; BIOLOGICAL MARKERS;

CLINICAL FEATURE; COUGHING; DISEASE SEVERITY; DYSPNEA; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION TEST; LUNG LAVAGE; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; PATHOPHYSIOLOGY; PREVALENCE; RESPIRATORY FUNCTION; REVIEW; SYSTEMIC SCLEROSIS; THORAX PAIN; COMPLICATION; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES, INTERSTITIAL; METABOLISM; METHODS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES, INTERSTITIAL; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 84920670899     PISSN: 07618417     EISSN: 17762561     Source Type: Journal    
DOI: 10.1016/j.pneumo.2014.09.003     Document Type: Review

References (92)

1. Jimenez S.A., Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004, 140:37-50.
2. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
3. Owens G.R., Fino G.J., Herbert D.L., Steen V.D., Medsger T.A., Pennock B.E., et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest 1983, 84:546-550.
4. Schurawitzki H., Stiglbauer R., Graninger W., Herold C., Pölzleitner D., Burghuber O.C., et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990, 176:755-759.
5. Tamaki T., Mori S., Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991, 283:366-371.
6. Vonk M.C., Broers B., Heijdra Y.F., Ton E., Snijder R., van Dijk A.P., et al. Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study. Ann Rheum Dis 2009, 68:961-965.
7. Garber S.J., Wells A.U., duBois R.M., Hansell D.M. Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis. Br J Radiol 1992, 65:983-986.
8. Ooi G.C., Mok M.Y., Tsang K.W., Wong Y., Khong P.L., Fung P.C., et al. Interstitial lung disease in systemic sclerosis. Acta Radiol 2003, 44:258-264.
9. Goldin J.G., Lynch D.A., Strollo D.C., Suh R.D., Schraufnagel D.E., Clements P.J., et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008, 134:358-367.
10. D'Angelo W.A., Fries J.F., Masi A.T., Shulman L.E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969, 46:428-440.
11. Weaver A.L., Divertie M.B., Titus J.L. Pulmonary scleroderma. Dis Chest 1968, 54:490-498.
12. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437-2444.
13. Sahhar J., Littlejohn G., Conron M. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Intern Med J 2004, 34:626-638.
14. Wells A.U., Steen V., Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009, 48:iii40-iii44.
15. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
16. Steen V.D., Conte C., Owens G.R., Medsger T.A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283-1289.
17. Steen V.D., Lanz J.K., Conte C., Owens G.R., Medsger T.A. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994, 37:1290-1296.
18. Harrison N.K., Glanville A.R., Strickland B., Haslam P.L., Corrin B., Addis B.J., et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med 1989, 83:403-414.
19. Arroliga A.C., Podell D.N., Matthay R.A. Pulmonary manifestations of scleroderma. J Thorac Imaging 1992, 7:30-45.
20. Remy-Jardin M., Remy J., Wallaert B., Bataille D., Hatron P.Y. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993, 188:499-506.
21. Austin J.H., Muller N.L., Friedman P., Hansell D.M., Naidich D.P., Remy-Jardin M., et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature committee of the Fleischner Society. Radiology 1996, 200:327-331.
22. Desai S.R., Veeraraghavan S., Hansell D.M., Nikolakopolou A., Goh N.S., Nicholson A.G., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560-567.
23. Wells A.U., Hansell D.M., Corrin B., Harrison N.K., Goldstraw P., Black C.M., et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992, 47:738-742.
24. Kazerooni E.A., Martinez F.J., Flint A., Jamadar D.A., Gross B.H., Spizarny D.L., et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977-983.
25. Launay D., Remy-Jardin M., Michon-Pasturel U., Mastora I., Hachulla E., Lambert M., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33:1789-1801.
26. Highland K.B., Silver R.M. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005, 17:737-745.
27. Wells A.U. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford) 2008, 47:v59-v61.
28. Pellegrino R., Viegi V., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
29. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
30. King T.E., Safrin S., Starko K.M., Brown K.K., Noble P.W., Raghu G., et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005, 127:171-177.
31. Plastiras S.C., Karadimitrakis S.P., Ziakas P.D., Vlachoyiannopoulos P.G., Moutsopoulos H.M., Tzelepis G.E. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006, 55:598-602.
32. Khanna D., Seibold J.R., Wells A., Distler O., Allanore Y., Denton C., et al. Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev 2010, 6:138-144.
33. Gilson M., Zerkak D., Wipff J., Dusser D., Dinh-Xuan A.T., Abitbol V., et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105cases. Eur Respir J 2010, 35:112-117.
34. Roughton F.J., Forster R.E. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol 1957, 11:290-302.
35. Steen V.D., Graham G., Conte C., Owens G., Medsger T.A. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992, 35:765-770.
36. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003, 62:97-99.
37. Steen V., Medsger T.A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516-522.
38. Chetta A., Aiello M., Foresi A., Marangio E., D'Ippolito R., Castagnaro A., et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18:170-175.
39. Villalba W.O., Sampaio-Barros P.D., Pereira M.C., Cerqueira E.M., Leme C.A., Marques-Neto J.F., et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007, 131:217-222.
40. Garin M.C., Highland K.B., Silver R.M., Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009, 36:330-336.
41. Buch M.H., Denton C.P., Furst D.E., Guillevin L., Rubin L.J., Wells A.U., et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007, 66:169-173.
42. Avouac J., Kowal-Bielecka O., Pittrow D., Huscher D., Behrens F., Denton C.P., et al. Validation of the 6min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010, 69:1360-1363.
43. Schoindre Y., Meune C., Dinh-Xuan A.T., Avouac J., Kahan A., Allanore Y. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009, 36:1481-1485.
44. Kowal-Bielecka O., Kowal K., Highland K.B., Silver R.M. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum 2010, 40:73-88.
45. Silver R.M., Miller K.S., Kinsella M.B., Smith E.A., Schabel S.I. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990, 88:470-476.
46. Warrick J.H., Bhalla M., Schabel S.I., Silver R.M. High resolution computed tomography in early scleroderma lung disease. J Rheumatol 1991, 18:1520-1528.
47. Wells A.U., Hansell D.M., Rubens M.B., Cullinan P., Haslam P.L., Black C.M., et al. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. Am J Respir Crit Care Med 1994, 150:462-468.
48. Behr J., Vogelmeier C., Beinert T., Meurer M., Krombach F., König G., et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154:400-406.
49. Witt C., Borges A.C., John M., Fietze I., Baumann G., Krause A. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999, 58:635-640.
50. Strange C., Bolster M.B., Roth M.D., Silver R.M., Theodore A., Goldin J., et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91-98.
51. Gustafsson R., Fredens K., Nettelbladt O., Hällgren R. Eosinophil activation in systemic sclerosis. Arthritis Rheum 1991, 34:414-422.
52. Wells A.U., Hansell D.M., Haslam P.L., Rubens M.B., Cailes J., Black C.M., et al. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. Am J Respir Crit Care Med 1998, 157:1474-1482.
53. White B., Moore W.C., Wigley F.M., Xiao H.Q., Wise R.A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947-954.
54. Schmidt K., Martinez-Gamboa L., Meier S., Witt C., Meisel C., Hanitsch L.G., et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009, 11:R111.
55. Rossi G.A., Bitterman P.B., Rennard S.I., Ferrans V.J., Crystal R.G. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985, 131:612-617.
56. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003, 29:371-390.
57. Harrison N.K., Myers A.R., Corrin B., Soosay G., Dewar A., Black C.M., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991, 144:706-713.
58. Travis W.D., Costabel U., Hansell D.M., King T.E., Lynch D.A., Nicholson A.G., et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188:733-748.
59. Fujita J., Yoshinouchi T., Ohtsuki Y., Tokuda M., Yang Y., Yamadori I., et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001, 60:281-283.
60. Kim D.S., Yoo B., Lee J.S., Kim E.K., Lim C.M., Lee S.D., et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121-127.
61. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581-1586.
62. Takahashi H., Kuroki Y., Tanaka H., Saito T., Kurokawa K., Chiba H., et al. Serum levels of surfactant proteins A and D are useful biomarkers for interstitial lung disease in patients with progressive systemic sclerosis. Am J Respir Crit Care Med 2000, 162:258-263.
63. Hant F.N., Ludwicka-Bradley A., Wang H.J., Li N., Elashoff R., Tashkin D.P., et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009, 36:773-780.
64. Asano Y., Ihn H., Yamane K., Yazawa N., Kubo M., Fujimoto M., et al. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum 2001, 44:1363-1369.
65. Maeda M., Ichiki Y., Aoyama Y., Kitajima Y. Surfactant protein D (SP-D) and systemic scleroderma (SSc). J Dermatol 2001, 28:467-474.
66. Yanaba K., Hasegawa M., Hamaguchi Y., Fujimoto M., Takehara K., Sato S. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol 2003, 21:429-436.
67. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006, 73:490-494.
68. Castro S.V., Jimenez S.A. Biomarkers in systemic sclerosis. Biomark Med 2010, 4:133-147.
69. Luzina I.G., Tsymbalyuk N., Choi J., Hasday J.D., Atamas S.P. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006, 206:221-228.
70. Prasse A., Pechkovsky D.V., Toews G.B., Jungraithmayr W., Kollert F., Goldmann T., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006, 173:781-792.
71. Kodera M., Hasegawa M., Komura K., Yanaba K., Takehara K., Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum 2005, 52:2889-2896.
72. Prasse A., Pechkovsky D.V., Toews G.B., Schäfer M., Eggeling S., Ludwig C., et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 2007, 56:1685-1693.
73. Tiev K.P., Hua-Huy T., Kettaneh A., Gain M., Duong-Quy S., Tolédano C., et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011, 38:1355-1360.
74. Kuryliszyn-Moskal A., Klimiuk P.A., Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement. Clin Rheumatol 2005, 24:111-116.
75. Vancheeswaran R., Magoulas T., Efrat G., Wheeler-Jones C., Olsen I., Penny R., et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction?. J Rheumatol 1994, 21:1838-1844.
76. Kumánovics G., Minier T., Radics J., Pálinkás L., Berki T., Czirják L. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol 2008, 26:414-420.
77. Wells A.U., Rubens M.B., du Bois R.M., Hansell D.M. Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Eur Respir J 1997, 10:280-285.
78. Fajac I., Kahan A., Menkès C.J., Dessanges J.F., Dall'Ava-Santucci J., Dinh-Xuan A.T. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998, 16:547-552.
79. Kharitonov S.A., Cailes J.B., Black C.M., du Bois R.M., Barnes P.J. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997, 52:1051-1055.
80. Paredi P., Kharitonov S.A., Loukides S., Pantelidis P., du Bois R.M., Barnes P.J. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999, 115:1352-1356.
81. Rolla G., Colagrande P., Scappaticci E., Chiavassa G., Dutto L., Cannizzo S., et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000, 27:1693-1698.
82. Moodley Y.P., Lalloo U.G. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001, 119:1449-1454.
83. Tsoukias N.M., George S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol (1985) 1998, 85:653-666.
84. Tiev K.P., Cabane J., Aubourg F., Kettaneh A., Ziani M., Mouthon L., et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007, 30:26-30.
85. Girgis R.E., Gugnani M.K., Abrams J., Mayes M.D. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002, 165:1587-1591.
86. Wuttge D.M., Bozovic G., Hesselstrand R., Aronsson D., Bjermer L., Scheja A., et al. Increased alveolar nitric oxide in early systemic sclerosis. Clin Exp Rheumatol 2010, 28:S5-S9.
87. Tiev K.P., Hua-Huy T., Rivière S., Le-Dong N.N., Febvre M., Cabane J., et al. High alveolar concentration of nitric oxide is associated with alveolitis in scleroderma. Nitric Oxide 2013, 28:65-70.
88. Tiev K.P., Le-Dong N.N., Duong-Quy S., Hua-Huy T., Cabane J., Dinh-Xuan A.T. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide 2009, 20:200-206.
89. Tiev K.P., Coste J., Ziani M., Aubourg F., Cabane J., Dinh-Xuan A.T. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2009, 26:32-38.
90. Tiev K.P., Hua-Huy T., Kettaneh A., Allanore Y., Le-Dong N.N., Duong-Quy S., et al. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. Thorax 2012, 67:157-163.
91. Hua-Huy T., Tiev K.P., Chéreau C., Duong-Quy S., Cabane J., Dinh-Xuan A.T. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. J Rheumatol 2010, 37:1680-1687.
92. Tiev K.P., Rivière S., Hua-Huy T., Cabane J., Dinh-Xuan A.T. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease. Nitric Oxide 2014, 40:17-21.